SUBMIT BOOK PROPOSAL
Online Store
benthambooks logo

Site Breadcrumb

Frontiers in Clinical Drug Research-Hematology
View Sample

Editor: Atta-ur-Rahman FRS

Frontiers in Clinical Drug Research-Hematology

Volume 5
eBook: US $69 Special Offer (PDF + Printed Copy): US $110
Printed Copy: US $76
Library License: US $276
ISSN: 2467-9585 (Print)
ISSN: 2352-3239 (Online)
ISBN: 978-981-5039-54-2 (Print)
ISBN: 978-981-5039-53-5 (Online)
Year of Publication: 2022
DOI: 10.2174/97898150395351220501
Rate This Book

Introduction

Frontiers in Clinical Drug Research – Hematology is a book series that brings updated reviews to readers interested in learning about advances in the development of pharmaceutical agents for the treatment of hematological disorders. The scope of the book series covers a range of topics including the medicinal chemistry, pharmacology, molecular biology and biochemistry of natural and synthetic drugs employed in the treatment of anemias, coagulopathies, vascular diseases and hematological malignancies. Reviews in this series also include research on specific antibody targets, therapeutic methods, genetic hemoglobinopathies and pre-clinical / clinical findings on novel pharmaceutical agents. Frontiers in Clinical Drug Research – Hematology is a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critically important information for developing clinical trials and devising research plans in the field of hematology, oncology and vascular pharmacology.

The fifth volume of this series features 7 reviews with a focus on thalassemia treatment and preeclampsia among other topics.

  • - Recent advances in the diagnosis and management of pulmonary embolism
  • - An evidence-based approach to treatment with iron chelators in transfusion- dependent thalassemia patients: present trends and future scenario
  • - Current and future treatments of iron overload in thalassemia patients
  • - Preeclampsia: biological and clinical aspects
  • - Haematological modulations by fixed dose combination (FDC) of tramadol hydrochloride/paracetamol (THP)
  • - Possible use of eculizumab in critically ill patients infected with covid-19 role of complement c5, neutrophils, and nets in the induction DIC, sepsis, and MOF hematological markers
  • - Emerging diagnostic and therapeutic targets in preeclampsia

eBook: US $69 Special Offer: US $110 Printed Copy: US $76 Library License: US $276

Preface

The fifth volume of the book series: Frontiers in Clinical Drug Research – Hematology comprises seven comprehensive chapters covering various important topics. These include diagnosis and management of pulmonary embolism, treatment of thalassemia patients with iron chelators, treatment of iron overload in thalassemia patients, biological and clinical aspects of preeclampsia, haematological modulations, use of eculizumab, and hematological markers used as therapeutic targets in preeclampsia.

In Chapter 1, Gunasekaran and Rahi summarize advances in the diagnosis and management of pulmonary embolism. Babu and Panachiyil describe an evidence-based approach to treat transfusion- dependent thalassemia patients with iron chelators in chapter 2 of the book. Chattipakorn et al., in chapter 3, review the current and future treatments of iron overload in thalassemia patients. In the next chapter Kannan et al., discuss biological and clinical aspects of preeclampsia. Chattopadhyay et al., in chapter 5 briefly describe the haematological modulations by fixed dose combination (FDC) of tramadol hydrochloride/paracetamol (THP). Lazarowski, in chapter 6 of the book explains the possible use of eculizumab in patients infected with COVID-19 and the role of complement C5, neutrophils, and neutrophil extracellular traps (NETs) in the induction disseminated intravascular coagulation (DIC), sepsis, and multiple organ failure (MOF). Ali and Khaliq in the last chapter of the book present the role of hematological markers as emerging diagnostic and therapeutic targets in preeclampsia.

I hope that the readers will find value in this collection of reviews and draw inspiration for conducting further drug discovery research in the field of hematology.

I am grateful for the timely efforts made by the editorial personnel of Bentham Science Publishers, especially Mr. Mahmood Alam (Editorial Director), Mr. Obaid Sadiq (Incharge Books Department) and Ms. Asma Ahmed (Senior Manager Publications).

Prof. Atta-ur-Rahman, FRS
Honorary Life Fellow, Kings College
University of Cambridge
Cambridge
UK